48 results about "Guinea pig" patented technology

The utility model discloses a device for freezing a guinea pig trachea through liquid nitrogen spray under a bronchoscope. A cold source device is mounted at one end of the first pipe body, and a nozzle is mounted at the other end of the first pipe body and extends into a guinea pig air pipe; one end of the second tube body is provided with a display screen, and the other end of the second tube body is provided with a lens which is in signal connection with the display screen and extends into the trachea of the guinea pig. The spray head extends into the trachea of an experimental animal, liquid nitrogen in the liquid nitrogen high-pressure storage tank is sprayed into the trachea of a guinea pig from the spray head through the first pipe body, a freezing experiment can be carried out on the trachea of the guinea pig, meanwhile, the lens also extends into the trachea of the guinea pig, and the lens transmits the freezing condition in the trachea of the guinea pig to the display screen. The freezing condition and the treatment condition in the trachea can be observed on the display screen in real time, the trachea of a guinea pig, a rat, a mouse and other small animals can be effectively subjected to freezing treatment, and the treatment condition can be observed in real time.

The invention discloses an application of a compound fresh bamboo juice in a guinea pig asthma model, and relates to the field of medicines, a Hartley albino guinea pig is adopted to construct an OVA induced asthma model, and the model is verified to be successfully constructed through evaluation indexes; evaluating the efficacy of the successfully constructed guinea pig asthma model by using different doses of compound fresh bamboo juice, and evaluating the efficacy of the guinea pig asthma model by scoring guinea pig capsaicin stimulation cough inducing times, alveolar lavage fluid leukocyte number, inflammatory factor content, lung tissue hydroxyproline content and behavioral signs. And evaluating the treatment effect of the compound fresh bamboo juice through Western blot detection, lung histopathology and immunofluorescence staining indexes. In a guinea pig asthma model, high-dose and medium-dose groups of the compound fresh bamboo juice can be used for remarkably reducing the number of cough, reducing the number of white blood cells in alveolar lavage fluid and the level of inflammatory factors and inhibiting pulmonary fibrosis, and a good treatment effect is shown. The results provide powerful support for potential application of the compound fresh bamboo juice in asthma treatment.

The invention discloses an application and a preparation of a miR-125b-5p inhibitor or antagonist for treating and / or preventing myopia. According to the application, a miR-125b-5p inhibitor or antagonist, particularly miR-125b-5p antiagomir with a nucleotide sequence as shown in SEQ ID NO: 8, is used for inhibiting the expression of miR-125b-5p in sclera and increasing the expression of a target gene tp53, so that the transdifferentiation of sclera fibroblasts can be remarkably reduced, sclera remodeling can be reduced, and the diopter reduction and ocular axis extension of guinea pig deprivation myopia can be retarded; the composition can be used for preventing myopia and controlling myopia progress, has the advantages of low administration frequency and high safety, and provides a safer, more effective and more convenient prevention and control means for myopia patients, especially teenagers.

1. The name of this design product: Eyeglass frame (guinea pig). 2. Purpose of this design product: used to store glasses. 3. The key point of the design of this product lies in its shape. 4. The picture or photo that best illustrates the design points: three-dimensional picture.

This invention relates to a guinea pig model of chronic obstructive pulmonary disease (COPD) with chronic bronchitis, its preparation method, and its application. Specifically, this invention provides a guinea pig model of COPD with chronic bronchitis, established by subjecting guinea pigs to at least two intratracheal infusions of lipopolysaccharide (LPS) combined with repeated exposure to cigarette smoke. This results in the guinea pigs exhibiting pathophysiological characteristics consistent with those of COPD with chronic bronchitis in terms of cough sensitivity, airway inflammation, airway hypersecretion, lung function, and histopathology. This lays a solid foundation for in-depth research and drug screening of COPD with chronic bronchitis.

The invention relates to a polypeptide for treating rhinitis as well as a preparation method and application thereof, and belongs to the technical field of biology. Natural active small molecule polypeptides are extracted from white tea plants, and the polypeptides are safe and non-toxic to cells and have remarkable bacteriostasis and sterilization effects on rhinitis pathogenic bacteria such as staphylococcus aureus, pseudomonas aeruginosa, candida albicans and aspergillus niger; in addition, in a guinea pig in-vivo test, symptoms of allergic rhinitis and inflammatory factors such as IgE, IL6 and IFN-gamma can be remarkably improved, and the treatment effect is superior to or equivalent to that of a positive control group. The white tea polypeptide disclosed by the invention has a remarkable effect of treating rhinitis, provides a novel, safe and efficient treatment choice for rhinitis patients, and has important scientific value and clinical application prospect.

The invention discloses an antibacterial peptide, a preparation method and application thereof and an antibacterial drug, and relates to the technical field of antibacterial peptides, the amino acid sequence of the antibacterial peptide is NH2-RRWRIVLIRARK-CONH2, and the preparation method is a polypeptide solid-phase synthesis method. The antibacterial peptide is wide in acid-base stability range from pH 2 to pH 9; the temperature stability range is wide and ranges from-20 DEG C to 50 DEG C; 95% ethanol resistance is realized; the shelf life is stable and exceeds 6 months. According to the antibacterial peptide provided by the invention, the trichophyton mentagrophytes are killed by inhibiting spore germination of the trichophyton mentagrophytes and causing hypha breakage, the trichophyton mentagrophytes do not generate drug resistance to the antibacterial peptide, the 1% concentration of the antibacterial peptide has an obvious treatment effect on a guinea pig model infected by the trichophyton mentagrophytes, and the antibacterial peptide has a good application prospect as a novel candidate drug for treating trichophyton mentagrophytes infection.

The invention discloses a pharmacodynamic test method for a cough relieving mixture, which comprises the following steps: constructing four core pharmacodynamic test sub-models containing ammonia water to cause young mouse cough, citric acid to cause young guinea pig cough, rabbit in-vitro trachea cilia mucus movement and young mouse trachea phenol red excretion and a body model of a test result analysis sub-model; each pharmacodynamic test sub-model is provided with a plurality of groups of test arrays and test individuals; pathogen data is imported to generate a simulated disease scene, and a corresponding drug sequence is called to intervene and collect physiological index change data; and multi-dimensional pharmacodynamic parameters are evaluated through the analysis sub-model, and a dose-effect relation curve and an evaluation report are generated. According to the invention, a parallel verification system for antitussive and expectorant tests is formed, the antitussive effective dose, the expectorant effective dose and the effective dose range under the dual action of the medicine are determined through multi-model cross validation, the accuracy degree of judging the effectiveness of the medicine is greatly improved, and a reliable method support is provided for evaluating the efficacy of the cough-stopping mixture.

The application provides a preparation method of Artemisia sphaerocephala pollen allergen and an Artemisia sphaerocephala pollen allergen injection, and belongs to the technical field of pollen allergen vaccine preparation. After the Artemisia sphaerocephala pollen is defatted and dried, the Artemisia sphaerocephala pollen is extracted by using an extraction solution, the supernatant is filled into a dialysis bag to be dialyzed, concentrated, enzymolyzed and desalted, and then chromatography is carried out, and polypeptides with molecular weights of 23-46KD and 67-82KD are collected to be the Artemisia sphaerocephala pollen allergen. The Artemisia sphaerocephala pollen allergen injection comprises the Artemisia sphaerocephala pollen allergen, sodium chloride, PBS buffer, phenol and thiourea. The Artemisia sphaerocephala pollen allergen injection of the application fills the blank of Artemisia sphaerocephala pollen allergen injection, can effectively reduce the allergic degree of guinea pigs to Artemisia sphaerocephala pollen, and can be stably stored at 2-8 DEG C.

The invention pertains to pet care products, specifically: litter box fillers for animals (cats, hamsters, rabbits, guinea pigs, terrariums, and others) living in human dwellings, and can also be used as bedding / flooring in chicken coops, horse stables, and livestock farms. The animal litter box filler is manufactured in granular form from recycled waste paper in the form of newspapers, books, corrugated cardboard, and natural additives. The raw material undergoes a series of steps: shredding, fluffing, and moistening to 15-25%, resulting in finished granules with a diameter of 4-12 mm and a length of 6-18 mm. The filler manufacturing process includes preliminary raw material sorting, subsequent shredding, fluffing, moistening, and then granulation and cooling of the granules. In the granulation machine, the raw material is pressed through round openings using a die die.The technical result consists of expanding the range of fillers and increasing the filler absorbency, as well as increasing the service life when stored in a dry place and convenient disposal into the sewer system or food waste for further processing.

The invention belongs to the technical field of animal model construction, and particularly relates to a spinal cord hypertension syndrome disease model modeling method and application. A guinea pig or a macaque is used as an experimental animal, and a composite biostimulation material and an accurate pressure regulation and control modeling system are combined to realize modeling. The composite biostimulation material is composed of a core pressure slow-release layer, a middle biocompatible coating and a surface targeting binding layer, has excellent biocompatibility, degradability and targeting property, and can reduce non-specific inflammatory response; the precise pressure regulation and control modeling system comprises a pressure sensing module, a micro-injection module, a real-time monitoring module and a main control module, and can dynamically regulate and control the pressure in the spinal cord in a closed-loop mode. The modeling method is easy and convenient to operate and good in repeatability, the model building success rate exceeds 95%, the pathological features are highly similar to clinical features and can last for 4 weeks, a reliable experimental model is provided for mechanism research, drug screening and therapeutic schedule evaluation of the spinal cord high pressure syndrome, and the modeling method is suitable for large-scale popularization.

The utility model belongs to the field of experimental animal equipment, and particularly relates to a guinea pig fixing frame which comprises a bottom plate, an operation table is arranged above the bottom plate, an adjusting frame is arranged between the bottom plate and the operation table, and the adjusting frame can change the inclination angle of the operation table and the height of the operation table. A plurality of adjusting holes are formed in the operating table and used for fixing four limbs of a guinea pig, and an elastic belt is further arranged on the operating table; the adjusting frame comprises two first supports and two second supports, the two first supports are oppositely arranged, the two second supports are oppositely arranged, the tops of the first supports are fixed to the bottom of the operation table, the bottoms of the first supports are fixed to the bottom plate, a hinge support is arranged between the two first supports, and the hinge support comprises a connecting rod and a sliding rod. One end of the connecting rod is connected to the first support, the other end of the connecting rod is connected with the end of the sliding rod, and the connecting rod is connected with the first support through a screw. The guinea pig fixing device can safely and stably fix a guinea pig, and experiment operators are prevented from being scratched by the guinea pig.

This invention relates to the field of microbial technology, specifically disclosing a thermoresistant Aeromonas verrucosa phage, its screening method, and its applications. The phage is deposited under CGMCC No. 47009. This phage belongs to the Myocaudidae family and exhibits significant heat resistance, maintaining a titer of 10 even after treatment at 70°C for 60 minutes. ^ 8 This bacteriophage exhibits a PFU / mL concentration above [amount missing] and can withstand the high temperatures of feed pelleting. It displays broad-spectrum lytic activity against *Aeromonas vesiculosus* and can cross-lyze *Aeromonas guinea pig* and *Aeromonas hydrophila*. This invention also provides a rapid screening method for this heat-resistant bacteriophage. Through a cycle of instantaneous heat treatment at 70°C followed by rapid cooling in an ice bath, genetically stable bacteriophages can be obtained within 5 days, solving the problems of long cycles and poor stability associated with traditional acclimatization methods. The bacteriophage and composition of this invention can be used to prepare veterinary drugs and disinfectants for the prevention and treatment of aquatic aeromonas diseases, showing broad application prospects.

The application belongs to the field of biological medicine, and particularly relates to an information bacteriocin array against small cell lung cancer and application thereof. Amino acid sequences such as SEQ ID NO: 1-30 are provided. A drug against small cell lung cancer is also provided, which comprises a fusion protein obtained by connecting a channel domain of colicin with polypeptides with amino acid sequences such as SEQ ID NO: 1-30. Pharmacodynamics experiments prove that in each growth cycle, a mouse tumor-bearing model cannot escape the recognition and killing of the information bacteriocin array composed of thirty kinds of fusion proteins. Guinea pig model experiments prove that the continuous use of the information bacteriocin array for 30 days does not produce any toxic side effects in the animal model. The information bacteriocin array can be used as an effective drug for treating small cell lung cancer.

The invention discloses compound beriberi powder as well as a preparation method and medical application thereof, and relates to the technical field of pharmaceutical preparations. The beriberi powder is prepared from 8 parts of salicylic acid powder, 6 parts of boric acid powder, 4 parts of benzoic acid powder, 1 part of tannic acid powder, 1 part of furacilin powder and 2 parts of radix sophorae flavescentis superfine powder, the radix sophorae flavescentis superfine powder is prepared by performing CO2 supercritical extraction on radix sophorae flavescentis and then performing spray drying, the particle size is smaller than or equal to 20 micrometers, and the mass content of radix sophorae flavescentis total alkaloids is larger than or equal to 15%. According to the invention, the ultra-fine pulverization and the high-content total alkaloid are cooperated with the organic acid and the antibacterial drug, so that the multi-target effects of bacteriostasis, itching relieving, convergence and cutin exfoliation are realized; the diameter of an in-vitro inhibition zone is greater than or equal to 22mm, the cure rate of a guinea pig model reaches 98%, and the skin irritation index is less than or equal to 0.2; the preparation is simple in process, stable in quality and suitable for treating and preventing dipping erosive, blister and keratinized beriberi.

The invention relates to a type II herpes simplex virus strain HSV-2 / KM-1 and application thereof, and belongs to the technical field of virus microorganisms. The II-type herpes simplex virus strain HSV-2 / KM-1 is preserved in the China Center for Type Culture Collection on July 25, 2025, and the preservation number of the II-type herpes simplex virus strain HSV-2 / KM-1 is CCTCC (China Center for Type Culture Collection) NO: V202550. The II-type herpes simplex virus strain HSV-2 / KM-1 disclosed by the invention has cell tropism and tends to infect genital epithelial cells; the II-type herpes simplex virus strain HSV-2 / KM-1 is applied to neutralizing antibody detection of mouse serum, and the instrumental effect of the II-type herpes simplex virus strain HSV-2 / KM-1 in immunogenicity evaluation of vaccines is disclosed. According to the invention, the II-type herpes simplex virus strain HSV-2 / KM-1 is simultaneously utilized to successfully construct a Hartley guinea pig genital herpes model or a BALB / c mouse genital herpes model, and the models can be used as new tools for HSV-2 vaccine evaluation.

1. Name of the designed product: Cowhide paper toy (guinea pig). 2. Use of the designed product: for toys. 3. Design points of the designed product: in shape. 4. Picture or photo best indicating the design points: perspective view.

The present invention discloses a strain of Lactobacillus mucosus from guinea pigs JL20 and its application, belonging to the field of biomedicine. Lactobacillus mucosus from guinea pigs JL20 was deposited in the General Microbiology Center of the China National Committee for the Collection of Microorganisms on July 19, 2023, with the deposit number CGMCC No. 27949. Lactobacillus mucosus from guinea pigs JL20 can be used as an adjuvant in leptospira vaccines, and has the effects of enhancing vaccine potency, improving antibody quality, and enhancing the reactivity of antigen-presenting cells. It is also convenient to administer, significantly reduces the vaccine dosage, reduces production costs, is safe and has no side effects, and reduces the production of inflammatory side effects caused by vaccine immunization, and has very important application value.

The invention discloses a nucleic acid preparation containing diketo dioxins, and belongs to the technical field of biological medicine. The technical problem to be solved is to improve the skin penetration absorption effect of the transdermal absorption promoting preparation and reduce the allergy and irritation. According to the technical scheme, the nucleic acid preparation is composed of an siRNA solution and a lipid solution. The siRNA solution contains siRNA (small interfering Ribonucleic Acid); the lipid solution comprises cationic lipid and a penetration enhancer; the penetration enhancer is a diketo dioxane compound, and has a structural formula as shown in a formula I in the specification. Experiments show that siRNA of a pharmaceutical composition containing the nucleic acid preparation, poloxamer, a thickening agent, a pH regulator and purified water is high in cumulative permeation amount, and a guinea pig Buehler test shows that the preparation is free of anaphylaxis and can effectively promote wound healing of diabetic mice, so that the nucleic acid preparation has large-scale production potential and value of rapid conversion into clinical application.

A pet nail filer device is disclosed, which is a nail rounder and smoother that can be applied to dogs, cats, rabbits, guineapigs, birds and other pet animals, etc., as needed. The pet nail filer device comprises a base component that is configured in a small, ergonomic, rounded cuboidal shape that is sized and shaped to be held in a palm of a user's hand with a hinged lid component. An interchangeable nail file component is releasably secured to the base component. The interchangeable nail file component is shaped like a small cup to fit an individual pet nail. The interchangeable nail file component comprises sandpaper like grit material within the cup cavity to safely file away the pet's nail. The interchangeable nail file component comes in a range of sizes and working mechanisms, ensuring that pet owners and groomers can find the perfect fit for their current animal.

This invention relates to the field of microbial technology, specifically to a thermoresistant Aeromonas guinea pig bacteriophage, its composition, and its applications. The bacteriophage was deposited on June 14, 2024, at the China General Microbiological Culture Collection Center (CGMCC), with accession number CGMCC No. 45946, and named RKP-AE24003. The composition comprises the aforementioned bacteriophage. The bacteriophage can be used to prepare products that kill or inhibit Aeromonas guinea pig; and products for the prevention and / or treatment of aquatic diseases caused by Aeromonas guinea pig. This bacteriophage RKP-AE24003 exhibits good thermoresistance and strong genetic stability, allowing for stable storage in high-temperature environments, significantly improving the stability of industrial production and its applicability to high-temperature scenarios.

The present application relates to the technical field of power distribution network, and more particularly to an adjustable resource aggregation method and device based on CPO algorithm, equipment and medium, the method comprising: obtaining power distribution network power flow data, and calculating the comprehensive voltage weakness of the power distribution network according to the power flow data; according to the comprehensive voltage weakness, the initial optimal cluster number is selected by using the CPO algorithm of the crown guinea pig optimizer, and the highest voltage weakness is selected as the initial cluster center; the initial optimal cluster number and the initial cluster center are clustered by using the K-means clustering algorithm, and the power distribution network is dynamically clustered by taking the electrical distance as the measurement distance. In the present application, the crown guinea pig optimizer CPO is used to improve the K-means clustering algorithm, and the power distribution network is dynamically clustered by taking the electrical distance as the measurement distance; the reasonable clustering of each branch of the power distribution network is realized. It is helpful to better understand the voltage distribution of the power distribution network, and provides strong guarantee for the safe and stable operation of the power grid.

The present invention belongs to the field of biomedicine, and specifically relates to a pheromonicin array against small cell lung cancer and the use thereof. Provided is a polypeptide having an amino acid sequence as shown in SEQ ID NOs: 1-30. Further provided is a drug against small cell lung cancer, which contains a fusion protein obtained by means of respectively connecting the channel domain of colicin to the polypeptide having the amino acid sequence as shown in SEQ ID NOs: 1-30. Pharmacodynamic experiments confirm that in each growth cycle, a tumor-bearing mouse model cannot escape the recognition and killing of tumors by the pheromonicin array consisting of 30 fusion proteins. Guinea pig model experiments confirm that the continuous use of the pheromonicin array for 30 days does not produce any toxic side effects in the animal model. The pheromonicin array can be used as an effective drug for treating small cell lung cancer.

The invention relates to the field of plant extracts, in particular to application of a hawthorn extract in preparation of a medicine for treating gall-stone. Dry hawthorn pulp is smashed, heated and extracted with an ethanol solution, filtered, concentrated and dried to obtain the hawthorn extract, the hawthorn extract can inhibit and treat gall-stone, the content of total bile acid (TBA) in a guinea pig gall-stone model is increased, the content of Ca < 2 + > and TBIL (total bilirubin) is reduced, and all indexes return to the normal level. In addition, the composite extract prepared by the invention and the combination of the composite extract and the hawthorn extract can effectively inhibit and treat gall-stone.

The application relates to a guinea pig head frame structure for astigmatism research and a mounting operation method and a preparation method thereof. Firstly, three-dimensional anatomical data of the head and neck of a guinea pig is acquired; a three-dimensional model of a head frame and a lens support is designed based on the data, and is formed by using an additive manufacturing process. The guinea pig head frame structure comprises the head frame and the lens support, the head frame is provided with a mouth and nose opening and a neck U-shaped ring; the lens support is provided with a lens clamping ring and is connected with the head frame. The head frame is sleeved on the head and neck of the guinea pig and is fixed by using a rope; an astigmatism experiment lens is pressed into the lens clamping ring; the experiment lens can be disassembled and eye medicine can be applied through a light transmission hole in a state of maintaining the fixation of the head frame. The application aims to overcome the technical problems that a current animal model molding device fixing mode in astigmatism experimental research is traumatic, complicated in operation, poor in stability and difficult to cooperate with eye medicine.

The utility model relates to the technical field of guinea pig breeding, and provides a simple guinea pig breeding cage which comprises a cage body, the cage body is composed of an upper cage part and a lower cage part in a detachable mode, the upper cage part is used for containing guinea pigs, the lower cage part is used for containing padding, a grid plate is arranged in the upper cage part, and the grid plate is arranged in the lower cage part. A material supporting plate capable of ascending and descending is arranged in the lower cage part; a padding layer is formed at the bottom of the lower cage part by lifting padding to a certain height through the retainer plate, when the padding is replaced, the stripper plate moves downwards firstly, the dirty padding moves downwards along with the stripper plate under the action of gravity and falls into the lower cage part, then the upper cage part and the lower cage part are split, guinea pigs stay in the upper cage part, then the dirty padding in the lower cage part is dumped and cleaned, and the guinea pigs are prevented from being damaged. When the guinea pig padding is replaced, new padding is laid, then the upper cage part and the lower cage part are spliced again, the material supporting plate moves upwards, the material supporting plate moves upwards to drive the padding to enter the bottom of the upper cage part to form a padding layer again, padding replacement is completed, operation is easy, and the guinea pig padding replacement efficiency is greatly improved.

The present invention belongs to the field of biomedicine, and specifically relates to a pheromonicin array against small cell lung cancer and the use thereof. Provided is a polypeptide having an amino acid sequence as shown in SEQ ID NOs: 1-30. Further provided is a drug against small cell lung cancer, which contains a fusion protein obtained by means of respectively connecting the channel domain of colicin to the polypeptide having the amino acid sequence as shown in SEQ ID NOs: 1-30. Pharmacodynamic experiments confirm that in each growth cycle, a tumor-bearing mouse model cannot escape the recognition and killing of tumors by the pheromonicin array consisting of 30 fusion proteins. Guinea pig model experiments confirm that the continuous use of the pheromonicin array for 30 days does not produce any toxic side effects in the animal model. The pheromonicin array can be used as an effective drug for treating small cell lung cancer.

The present application aims to overcome the shortcomings of the current guinea pig myopia induction model as much as possible, and develop an animal model which can focus on the core symptoms of juvenile myopia, and can well intervene and prevent and control the evaluation of myopia. In the construction method of the guinea pig myopia model of the present application, the guinea pig myopia model is obtained by high oxygen + high sugar and high protein feed + instillation of mixed solution of chain urea and sodium iodoacetate + light and dark stimulation + strong light stimulation. This non-single factor induced guinea pig myopia model is consistent with the view that myopia is induced by multiple factors in etiology, and can better simulate the characteristics of human myopia. The non-single factor induced guinea pig myopia model of the present application basically meets three effectivenesses, whether from the perspective of pathophysiological theory or from the perspective of simulating typical clinical symptoms and treatment prediction, it is a relatively ideal animal model, which will provide support for the pathogenesis of multiple factor induced myopia, and provide a theoretical basis for developing new solutions for myopia prevention and treatment.

Animal bedding, such as for a guinea pig, is disclosed. The animal bedding comprises a main section and a pocket. The main section includes a top layer, a middle layer, and a bottom layer. The top layer is hydrophobic, the middle layer is hydrophilic and at least a part of the bottom layer is hydrophobic. The top layer, the middle layer and the bottom layer are attached to one another, such as via stitching along a perimeter of the main section. Separately, the top layer and the middle layer are attached to one another, such as in an interior of the main section, to form quilting in the main section. The pocket, which is attached to the main section, allows the guinea pig to burrow therein.